Economic costs of antidepressant use: a population-based study in Sweden.

IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES
Linda Beckman, Laura von Kobyletzki, Mikael Svensson
{"title":"Economic costs of antidepressant use: a population-based study in Sweden.","authors":"Linda Beckman,&nbsp;Laura von Kobyletzki,&nbsp;Mikael Svensson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prescription of antidepressant drugs (ADs) has increased in recent decades, with rising costs for patients as well as for the health care system. There is sparse evidence of which factors explain the high economic costs and financial burden for the general population.</p><p><strong>Aims of the study: </strong>The aim was to assess individual-level determinants of out-of-pocket and total health care costs of AD use in the Swedish general population.</p><p><strong>Methods: </strong>We randomly sampled 400,000 individuals aged 18+ from Statistics Sweden's population register from 2010 to 2013. Two-part regression models were used for our two primary outcome variables: (i) total health care costs for AD use per year and individual, and (ii) total out-of-pocket costs of AD use per year and individual.</p><p><strong>Results: </strong>Women, the unemployed, unmarried people and residents of big cities have both higher use of ADs and higher associated total health care and out-of-pocket costs. Today, ADs are relatively inexpensive and average cost differences among all groups are therefore minor. The elderly have higher use of ADs, but are more commonly low-volume users and do not have higher total health care or out-of-pocket costs.</p><p><strong>Discussion and limitations: </strong>Groups with relatively low socioeconomic status are at risk of higher costs for antidepressant use. However, given the Swedish system of drug subsidies, differences in financial burden for individuals are minor. The limitations of this study included that we lacked data on diagnosis and could therefore not categorize the reasons for AD consumption. Furthermore, our results may not be generalized to other countries with a lower AD prevalence then Sweden's, since our estimates are dependent on the point prevalence of antidepressant use in the population.</p><p><strong>Implications for health care provision and use: </strong>Groups with higher AD consumption and economic costs may suffer from more severe depression owing to more risk factors and less social support in their surroundings, and may be in greater need of additional treatment and support than other groups.</p><p><strong>Implications for health policies and further research: </strong>Our results offer insight at an aggregate level, and more information on the underlying causes of higher costs is needed to discern the policy implications.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"22 4","pages":"125-130"},"PeriodicalIF":1.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Mental Health Policy and Economics","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prescription of antidepressant drugs (ADs) has increased in recent decades, with rising costs for patients as well as for the health care system. There is sparse evidence of which factors explain the high economic costs and financial burden for the general population.

Aims of the study: The aim was to assess individual-level determinants of out-of-pocket and total health care costs of AD use in the Swedish general population.

Methods: We randomly sampled 400,000 individuals aged 18+ from Statistics Sweden's population register from 2010 to 2013. Two-part regression models were used for our two primary outcome variables: (i) total health care costs for AD use per year and individual, and (ii) total out-of-pocket costs of AD use per year and individual.

Results: Women, the unemployed, unmarried people and residents of big cities have both higher use of ADs and higher associated total health care and out-of-pocket costs. Today, ADs are relatively inexpensive and average cost differences among all groups are therefore minor. The elderly have higher use of ADs, but are more commonly low-volume users and do not have higher total health care or out-of-pocket costs.

Discussion and limitations: Groups with relatively low socioeconomic status are at risk of higher costs for antidepressant use. However, given the Swedish system of drug subsidies, differences in financial burden for individuals are minor. The limitations of this study included that we lacked data on diagnosis and could therefore not categorize the reasons for AD consumption. Furthermore, our results may not be generalized to other countries with a lower AD prevalence then Sweden's, since our estimates are dependent on the point prevalence of antidepressant use in the population.

Implications for health care provision and use: Groups with higher AD consumption and economic costs may suffer from more severe depression owing to more risk factors and less social support in their surroundings, and may be in greater need of additional treatment and support than other groups.

Implications for health policies and further research: Our results offer insight at an aggregate level, and more information on the underlying causes of higher costs is needed to discern the policy implications.

抗抑郁药使用的经济成本:瑞典一项基于人群的研究。
背景:近几十年来,抗抑郁药物(ADs)的处方有所增加,患者和卫生保健系统的成本也在上升。很少有证据表明,哪些因素可以解释普通民众的高经济成本和财政负担。研究目的:目的是评估瑞典普通人群中AD使用的自费和总医疗费用的个人水平决定因素。方法:从瑞典统计局2010年至2013年的人口登记簿中随机抽取40万名18岁以上的成年人。两部分回归模型用于我们的两个主要结果变量:(i)每年和个人使用阿尔茨海默病的总医疗费用,以及(ii)每年和个人使用阿尔茨海默病的总自付费用。结果:女性、无业人员、未婚人员和大城市居民的ad使用率较高,相关的总医疗费用和自付费用也较高。今天,ADs相对便宜,因此所有群体之间的平均成本差异很小。老年人对ad的使用率更高,但更常见的是低剂量使用者,并且没有更高的总医疗保健费用或自付费用。讨论和限制:社会经济地位相对较低的群体使用抗抑郁药的风险较高。然而,鉴于瑞典的药品补贴制度,个人财政负担的差异很小。本研究的局限性包括我们缺乏诊断数据,因此无法对AD消费的原因进行分类。此外,我们的结果可能不能推广到其他AD患病率低于瑞典的国家,因为我们的估计依赖于人群中抗抑郁药使用的点患病率。对卫生保健提供和使用的影响:由于风险因素较多,周围社会支持较少,AD消费和经济成本较高的群体可能患有更严重的抑郁症,并且可能比其他群体更需要额外的治疗和支持。对卫生政策和进一步研究的影响:我们的结果提供了总体层面的见解,需要更多关于成本上升的潜在原因的信息来辨别政策影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
6.20%
发文量
8
期刊介绍: The Journal of Mental Health Policy and Economics publishes high quality empirical, analytical and methodologic papers focusing on the application of health and economic research and policy analysis in mental health. It offers an international forum to enable the different participants in mental health policy and economics - psychiatrists involved in research and care and other mental health workers, health services researchers, health economists, policy makers, public and private health providers, advocacy groups, and the pharmaceutical industry - to share common information in a common language.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信